True Wealth Design’s Lucid Diagnostics LUCD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$256 Buy
239
+233
+3,883% +$251 ﹤0.01% 2397
2026
Q1
$7 Buy
6
+4
+200% +$5 ﹤0.01% 2683
2025
Q4
$3 Buy
+2
New +$2 ﹤0.01% 2552

Other funds holding LUCD

True Wealth Design's LUCD Position: Q2 2026 in Review

True Wealth Design increased its Lucid Diagnostics (LUCD) stake by 3,883% in Q2 2026, buying an estimated $251 and bringing the position to 239 shares worth $256. The position accounts for ﹤0.01% of the portfolio, ranked #2397.

True Wealth Design first reported a position in LUCD in Q4 2025 and has held it in 3 quarters since. 8 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • True Wealth Design held 239 shares of Lucid Diagnostics worth $256 as of Q2 2026.
  • True Wealth Design bought 233 Lucid Diagnostics shares in Q2 2026, an estimated $251.
  • Lucid Diagnostics made up ﹤0.01% of True Wealth Design's portfolio in Q2 2026, its #2397 holding.
  • True Wealth Design first reported a position in Lucid Diagnostics in Q4 2025 and has held it in 3 quarters since.
  • 8 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on True Wealth Design's 13F filing for Q2 2026, filed 16 Jul 2026.